25Feb/14

InterMune's drug delays lung disease progression in trial – Reuters UK


The Almagest

InterMune’s drug delays lung disease progression in trial
Reuters UK
The drug is already approved to treat IPF in Europe and Canada, where it is marketed as Esbriet. It is also approved in Japan, South Korea, China, India, Argentina and Mexico. IPF is an irreversible condition that leads to progressive loss of lung
InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Wall Street Journal

all 9 news articles »

25Feb/14

InterMune lung drug passes trial, shares nearly triple – Reuters


MarketWatch (blog)

InterMune lung drug passes trial, shares nearly triple
Reuters
It is also approved in Japan, South Korea, China, India, Argentina and Mexico. IPF is an irreversible condition that leads to progressive loss of lung function due to scarring, which hinders a lung’s ability to absorb oxygen. InterMune said it expected
InterMune shares more than double on tests for lung-disease treatmentMarketWatch (blog)
InterMune more than doubles on lung-drug studyMSN Money
InterMune hits 2-year high on US Esbriet studyBusinessweek

all 48 news articles »

25Feb/14

Spouse's death could trigger heart attack – Times of India


Times of India

Spouse’s death could trigger heart attack
Times of India
The authors compared the rate of myocardial infarction (MI, heart attack) or stroke in older patients (n=30,447, 60 to 89 years of age) whose partner died to that of individuals (n=83,588) whose partners were still alive during the same period. Fifty
Spouse death may up risk of heart attack, strokeIndian Express
You are here! Home > SCIENCE and TECHNOLOGY > Partner’s death IANS

all 29 news articles »